• Pure Extracts Manufacturing Corp., has ordered more than 30,000 vape cartridges and vape pens for the Canadian market
  • Delivery is expected in the first week of April
  • Revenue estimates for this shipment are approximately $650,000
  • Pure Extracts is a plant-based extraction company, focused on cannabis, hemp, functional mushrooms, and the rapidly emerging psychedelic sector
  • Pure Extracts (PULL) opened trading at C$0.55 per share

Pure Extracts Technologies (PULL) subsidiary, Pure Extracts Manufacturing, has ordered more than 30,000 vape cartridges and vape pens for the Canadian market.

These vape products are expected to arrive at the company’s British Columbia facility in the first week of April. 

The cartridges will be filled with a selection of some of the Company’s 30+ proprietary, full-spectrum oil formulations.

Revenue estimates for this shipment are approximately $650,000.

Pure Extracts CEO, Ben Nikolaevsky, remarked,

“We are looking forward to building our vape pen inventory in preparation for our retail launch through established provincial distribution channels. At the same time, we plan to launch our Pure Chews brand of CBD and THC edible gummie products and we have been steadily accumulating all the components from the oil extracts to the flavouring to our proprietary packages.”

Pure Extracts features an all-new, state-of-the-art processing facility located near Whistler, British Columbia.

Pure Extracts is a plant-based extraction company, focused on cannabis, hemp, functional mushrooms, and the rapidly emerging psychedelic sector.

Pure Extracts (PULL) opened trading at C$0.55 per share.

More From The Market Online

Tilray Brands seeks US$250M for U.S. cannabis expansion

Global cannabis stock Tilray Brands (TSX:TLRY) intends to raise up to US$250 million to fund its U.S. expansion plan.

The Market Online’s Weekly Cannabis Report – May 17, 2024

This international biopharmaceutical company revealed it has completed the retrospective observational real-world evidence study.

Avicanna finishes study of CBD cream’s use for rare skin disorder

Avicanna (TSX:AVCN) completes an observational study of its RHO Phyto-branded Ultra CBD topical cream on patients with epidermolysis bullosa.